体重下降约25斤！诺和诺德(NVO.US)长效胰淀素3期结果公布

Core Insights - Novo Nordisk (NVO.US) presented subgroup analysis data from the Phase 3 REDEFINE 1 trial at the 2025 European Association for the Study of Diabetes (EASD) annual meeting, focusing on the efficacy and safety of 2.4 mg cagrilintide monotherapy combined with lifestyle intervention in overweight or obese adults without diabetes [1] - The analysis indicated that patients in the cagrilintide group experienced an average weight loss of approximately 12.5 kg [1] - Based on these results, Novo Nordisk plans to initiate the Phase 3 RENEW clinical trial for cagrilintide in the fourth quarter of this year [1] Company Insights - Cagrilintide is a next-generation long-acting amylin analog that mimics the naturally occurring amylin in the human body, differing in mechanism from currently approved GLP-1-based weight loss therapies [1] - Novo Nordisk is evaluating cagrilintide for weekly subcutaneous injection (recommended dose of 2.4 mg) for the treatment of overweight or obese adults [1]